TMCnet1d
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...
Opinion
FDA foot-dragging might have saved your hands, and you never knew it
The Trump administration is tearing down both regulations and the federal government that enforces them. The consequences will be enormous.
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...